Skyhawk's Dual-Targeting Pill Brings New Hope to Huntington's Patients

BOSTON, MA – November 05, 2026 – In my years observing the intersection of community support and institutional innovation, few areas of medicine have tested the resilience of patients and researchers quite like Huntington's disease. Huntington's is a family disease, a progressive neurodegenerative disorder caused by a genetic stutter—a CAG repeat expansion in the huntingtin gene. It systematically strips away movement, cognition, and function, leaving over 40,000 symptomatic Americans and hundreds of thousands worldwide in its wake. For decades, the therapeutic pipeline has offered little more than symptom management. But today, the narrative may be shifting.

Skyhawk Therapeutics has officially initiated U.S. patient dosing in its global pivotal FALCON-HD study evaluating SKY-0515, a novel investigational treatment for Huntington's disease. Dosing commenced at the CenExel Movement Disorder Center in Colorado, with additional sites, including Beth Israel Deaconess Medical Center, slated to begin in the coming weeks. To date, more than 50,000 doses of SKY-0515 have been administered across over 30 study sites in 10 countries, signaling a massive, coordinated effort to bring a potentially disease-modifying therapy to market.

Redefining the Approach to a Complex Foe

To understand why SKY-0515 is generating such cautious optimism among movement disorder specialists, one must look at the graveyard of past clinical trials. The Huntington's research landscape is littered with high-profile setbacks. Roche and Ionis saw their antisense oligonucleotide, tominersen, fail in Phase 3 trials due to an unfavorable benefit-risk profile. Wave Life Sciences halted early-generation programs after failing to significantly reduce mutant huntingtin protein. Novartis abandoned its oral candidate, branaplam, due to peripheral neuropathy side effects.

The challenge has always been the target. Traditional approaches largely focused on lowering the mutant huntingtin (mHTT) protein, the primary driver of the disease's pathology. Skyhawk's SKY-0515, an oral small molecule RNA splicing modifier, takes a dual-targeting approach. It is designed to reduce mHTT, but crucially, it also targets a protein called PMS1.

PMS1 is a key driver of somatic CAG repeat expansion. In simpler terms, the genetic stutter that causes Huntington's doesn't just sit statically in the DNA; it expands over time in certain cells, particularly in the brain's striatum. This somatic expansion accelerates cellular toxicity and disease progression. By lowering PMS1, SKY-0515 aims to halt this genetic snowball effect. For patients with high CAG repeat counts, this dual mechanism is not just an incremental improvement; it is a fundamental rethinking of how to stall the disease's underlying architecture.

Early data suggests this approach is working where others have stumbled. While competitors like PTC Therapeutics have shown a 43 percent suppression of huntingtin protein with their oral splicing modifier, PTC518, Skyhawk's Phase 1/2 trials demonstrated an average mHTT reduction of more than 60 percent at a 9-milligram dose. Furthermore, SKY-0515 achieved this without the peripheral neuropathy signals that doomed previous small molecule efforts.

The Human Impact of an Oral Alternative

Innovation is rarely just about the molecule itself; it is equally about how that molecule is delivered to the community. Currently, the most advanced therapies in the Huntington's pipeline are highly invasive. Antisense oligonucleotides like Alnylam's brezosiran require regular lumbar punctures to reach the central nervous system. Gene therapies, such as uniQure's AMT-130, require direct, irreversible surgical infusion into the brain.

While these approaches hold immense scientific merit, they present significant barriers to equitable community access. Rural patients, those without robust caregiving networks, or individuals in advanced stages of motor decline face monumental hurdles in accessing surgical or intrathecal treatments. An oral, once-daily pill like SKY-0515 democratizes access to disease-modifying care. It allows patients to maintain their dignity and independence, managing a complex neurological disease from their kitchen table rather than an operating room.

"The opening of U.S. sites in the pivotal FALCON-HD study is an important milestone for the U.S. Huntington's disease community, where there are still no approved therapies shown to slow the progression of the disease," said Samuel Frank, MD, Director of the Huntington's Disease Society of America Center of Excellence at Beth Israel Deaconess Medical Center and a FALCON-HD investigator. "SKY-0515 is designed to lower both mutant huntingtin and PMS1, two proteins implicated in HD pathology and progression, and the Phase 1/2 results to date have been very encouraging. We look forward to beginning dosing at Beth Israel Deaconess before end of 2026 and to offering eligible people with HD in the U.S. the opportunity to take part in this study."

Encouraging Signals from the Clinic

The optimism surrounding the FALCON-HD expansion is anchored in robust Phase 1/2 data. Skyhawk recently reported final 15-month results showing that SKY-0515 not only reduced toxic proteins but also translated those biological changes into measurable clinical benefits. Alongside the 60 percent drop in mHTT, the drug achieved a consistent 25 percent reduction in PMS1 mRNA.

Most importantly for patients and their families, the drug appears to alter the clinical trajectory of the disease. At month 15, patients treated with SKY-0515 demonstrated a 1.59-point improvement in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) compared to an overlap-weighted external natural history control. This composite scale measures a patient's functional capacity, motor skills, and cognitive processing. All four subcomponents of the scale favored the treatment group, with statistically significant improvements in total functional capacity and motor scores.

In a field accustomed to therapies that merely stabilize decline, a signal of functional improvement is exactly the kind of breakthrough researchers have been desperately seeking. And crucially, the drug was well-tolerated over the 15-month period, with no treatment-related serious adverse events reported.

"Bringing FALCON-HD to the U.S. is an important step toward our goal of delivering a once-daily oral, potentially disease-modifying treatment to people living with Huntington's disease," said Bill Haney, Co-founder and Chief Executive Officer of Skyhawk Therapeutics. "We are grateful to the participants, families and investigators whose commitment is making this study possible."

A Broader Test of Institutional Innovation

The transition of SKY-0515 into late-stage global trials is also a testament to the viability of Skyhawk's proprietary SKYSTAR platform. By utilizing computational biology and artificial intelligence, the company has engineered small molecules capable of crossing the blood-brain barrier to correct RNA mis-splicing. This represents a significant leap forward in institutional innovation, proving that targeted, oral therapies can address diseases traditionally thought to require complex biologic or genetic interventions.

The FALCON-HD pivotal program is a massive undertaking, reflecting the deep institutional investment required to combat rare neurodegenerative diseases. The program comprises two randomized, double-blind, placebo-controlled studies. The first, FALCON-HD 004-ANZ, has already completed enrollment with 144 Stage 2 and Stage 3 HD participants across Australia and New Zealand. The second, FALCON-HD 004-WW, is actively recruiting, with plans to enroll 400 participants across more than 40 global sites.

As dosing begins in the United States, the Huntington's community watches with a blend of hope and measured realism. We have been at the precipice of breakthroughs before, only to be pushed back by the unforgiving biology of the brain. Yet, the dual-targeting mechanism, the convenience of an oral pill, and the strong early clinical signals of SKY-0515 suggest that this time, the foundation is stronger. For the tens of thousands of families living in the shadow of this disease, true institutional support means relentless, innovative pursuit of a cure. With the expansion of the FALCON-HD trial, that pursuit has taken a profound and necessary step forward.